iTeos Therapeutics has developed a novel and potent best - in - class A2A blocker that has been specifically optimized for immuno - oncology indications to retain a high potency in the adenosine - rich environment found in tumors and to
restore cytokine production even in the presence of high concentrations of adenosine.